Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

被引：0

作者：

Baz, Rachid ^{[1
]}

Martin, Thomas G. ^{[2
]}

Alsina, Melissa ^{[1
]}

Shain, Kenneth H. ^{[1
]}

Cho, Hearn J. ^{[3
]}

Wolf, Jeffrey L. ^{[2
]}

Mahindra, Anuj ^{[2
]}

Chari, Ajai ^{[3
]}

Sullivan, Daniel M. ^{[4
]}

Nardelli, Lisa A. ^{[1
]}

Lau, Kenneth ^{[3
]}

Zhao, Xiuhua ^{[1
]}

Lin, Hui-Yi ^{[1
]}

Jagannath, Sundar ^{[3
]}

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[3] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Baz, Rachid C.
Martin, Thomas G., III
Lin, Hui-Yi
Zhao, Xiuhua
Shain, Kenneth H.
Cho, Hearn J.
Wolf, Jeffrey L.
Mahindra, Anuj
Chari, Ajai
Sullivan, Daniel M.
Nardelli, Lisa A.
Lau, Kenneth
Alsina, Melissa
Jagannath, Sundar
BLOOD, 2016, 127 (21) : 2561 - 2568
[2] A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
Van Oekelen, Oliver
Parekh, Samir
Cho, Hearn J.
Vishnuvardhan, Nivetha
Madduri, Deepu
Richter, Joshua
Ip, Chun
Lau, Kenneth
Florendo, Erika
Mancia, Ines S.
Thomas, Joanne
Verina, Daniel
Chan, Elaine
Zarychta, Katarzyna
La, Lisa
Strumolo, Gina
Melnekoff, David T.
Leshchenko, Violetta V.
Kim-Schulze, Seunghee
Couto, Suzana
Wang, Maria
Pierceall, William E.
Thakurta, Anjan
Lagana, Alessandro
Jagannath, Sundar
Chari, Ajai
LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2208 - 2215
[3] Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Garderet, Laurent
Kuhnowski, Frederique
Berge, Benoit
Roussel, Murielle
Escoffre-Barbe, Martine
Lafon, Ingrid
Facon, Thierry
Leleu, Xavier
Karlin, Lionel
Perrot, Aurore
Moreau, Philippe
Marit, Gerald
Stoppa, Anne-Marie
Royer, Bruno
Chaleteix, Carine
Tiab, Mourad
Araujo, Carla
Lenain, Pascal
Macro, Margaret
Voog, Eric
Benboubker, Lofti
Allangba, Olivier
Jourdan, Eric
Orsini-Piocelle, Frederique
Brechignac, Sabine
Eveillard, Jean-Richard
Belhadj, Karim
Wetterwald, Marc
Pegourie, Brigitte
Jaccard, Arnaud
Eisenmann, Jean-Claude
Glaisner, Sylvie
Mohty, Mohamad
Hulin, Cyrille
Avet-Loiseau, Herve
Mathiot, Claire
Attal, Michel
BLOOD, 2018, 132 (24) : 2555 - 2563
[4] Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma (vol 127, pg 2561, 2016)
Baz, R. C.
Martin, T. G., III
Lin, H-Y
BLOOD, 2016, 128 (03) : 461 - 461
[5] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Shah, Jatin J.
Stadtmauer, Edward A.
Abonour, Rafat
Cohen, Adam D.
Bensinger, William I.
Gasparetto, Cristina
Kaufman, Jonathan L.
Lentzsch, Suzanne
Vogl, Dan T.
Gomes, Christina L.
Pascucci, Natalia
Smith, David D.
Orlowski, Robert Z.
Durie, Brian G. M.
BLOOD, 2015, 126 (20) : 2284 - 2290
[6] Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study
Song, Yang
Kim, Jin Seok
Chim, C. S.
Lee, Je-Jung
Yoon, Sung-Soo
Ng, Soo Chin
Gan, Gin Gin
Handa, Hiroshi
Jen, Wei-Ying
Li, Xinhua
Pokharkar, Yogesh Mahadev
Durie, Brian G. M.
Chng, Wee-Joo
BLOOD, 2023, 142
[7] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Gasparetto, Cristina
Bowles, Kristian M.
Abdallah, Al-Ola
Morris, Lura
Mander, Gudrun
Coppola, Sheryl
Wang, Jing
Ross, Jeremy A.
Bueno, Orlando F.
Arriola, Emma
Mateos, Maria Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
[8] A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Chari, Ajai
Cho, Hearn Jay
Parekh, Samir
Lau, Kenneth
Morgan, Gillian
Catamero, Donna
Cortes, Melissa
Curtis, Meredith
Escalon, Juliet
Florendo, Erika
Verina, Daniel
Stevens, Nadege
Chan, Elaine
Garcia, Katarzyna
La, Lisa
Shields, Marisa
Strumolo, Gina
Jagannath, Sundar
BLOOD, 2016, 128 (22)
[9] Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
Richardson, Paul G.
Attal, Michel
Campana, Frank
Le-Guennec, Solenn
Hui, Ai-Min
Risse, Marie-Laure
Corzo, Kathryn
Anderson, Kenneth C.
FUTURE ONCOLOGY, 2018, 14 (11) : 1035 - 1047
[10] Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
Mark, Tomer M.
Forsberg, Peter A.
Rossi, Adriana C.
Pearse, Roger N.
Pekle, Karen A.
Perry, Arthur
Boyer, Angelique
Tegnestam, Linda
Jayabalan, David
Coleman, Morton
Niesvizky, Ruben
BLOOD ADVANCES, 2019, 3 (04) : 603 - 611

← 1 2 3 4 5 →